Interesting analysis of the haemophilia R and D and opportunities for CSL
Target price $60
"Products to boost earnings by 7.5%, but potentially up to 30%: For each market segment we have examined a range of scenarios, based on the outcome of key clinical trials. Using what we think are conservative assumptions, we calculate a probability-weighted impact of +7.5% for CSL from its R&D haemophilia portfolio. If, however, CSL is successful in bringing its factor 7a, 8 and 9 to market, we believe earnings will increase by +29%."
http://www.macquarie.com.au/dafiles/Internet/mgl/au/apps/retail-newsletter/docs/2012_12/CSL171212e.pdf
macquarie haemophilia market research
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$297.50 |
Change
2.600(0.88%) |
Mkt cap ! $143.7B | |||
| Open | High | Low | Value | Volume |
| $297.44 | $299.00 | $297.16 | $161.2M | 541.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 944 | $297.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $297.50 | 1699 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |